BioCryst Pharmaceuticals’ (BCRX) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report released on Tuesday,Benzinga reports. They currently have a $14.00 price target on the biotechnology company’s stock.

A number of other equities analysts also recently issued reports on the company. JMP Securities upped their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Finally, StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $14.67.

BioCryst Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ BCRX opened at $7.67 on Tuesday. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88. The stock’s fifty day simple moving average is $7.78 and its two-hundred day simple moving average is $6.98. The stock has a market capitalization of $1.59 billion, a PE ratio of -12.57 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter last year, the firm earned ($0.19) EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% on a year-over-year basis. On average, equities analysts predict that BioCryst Pharmaceuticals will post -0.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C grew its position in BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after purchasing an additional 3,140,804 shares during the period. Kynam Capital Management LP grew its holdings in BioCryst Pharmaceuticals by 41.9% during the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock worth $33,160,000 after acquiring an additional 1,927,491 shares during the period. Rice Hall James & Associates LLC raised its position in BioCryst Pharmaceuticals by 4.0% during the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after acquiring an additional 84,102 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in BioCryst Pharmaceuticals by 528.0% in the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock valued at $6,874,000 after acquiring an additional 935,132 shares during the period. Finally, Sarissa Capital Management LP boosted its position in BioCryst Pharmaceuticals by 9.4% in the 1st quarter. Sarissa Capital Management LP now owns 1,094,168 shares of the biotechnology company’s stock worth $5,558,000 after purchasing an additional 94,168 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.